These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 2087415)

  • 1. Erythroblastosis fetalis produced by Kell immunization: dental findings.
    Cullen CL
    Pediatr Dent; 1990; 12(6):393-6. PubMed ID: 2087415
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Enamel hypoplasia and essential staining of teeth from erythroblastosis fetalis.
    Atasu M; Genc A; Ercalik S
    J Clin Pediatr Dent; 1998; 22(3):249-52. PubMed ID: 9641102
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Kell alloimmunization, hemolytic disease of the newborn, and perinatal management.
    Wenk RE; Goldstein P; Felix JK
    Obstet Gynecol; 1985 Oct; 66(4):473-6. PubMed ID: 3931011
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hemolytic disease of the newborn caused by irregular blood subgroup (Kell, C, c, E, and e) incompatibilities: report of 106 cases at a tertiary-care centre.
    Karagol BS; Zenciroglu A; Okumus N; Karadag N; Dursun A; Hakan N
    Am J Perinatol; 2012 Jun; 29(6):449-54. PubMed ID: 22399212
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Clinical follow-up studies on late prognosis of Rh-related hemolytic disease of the newborn. II. Stomatologic findings].
    Solyga P
    Padiatr Grenzgeb; 1970; 9(3):162-75. PubMed ID: 5534906
    [No Abstract]   [Full Text] [Related]  

  • 6. [Late damage after Rh-erythroblastosis, ABO-erythroblastosis and hyperbilirubinemia in the neonate (author's transl)].
    Weber H; Ströder J
    Klin Padiatr; 1973 Sep; 185(5):383-99. PubMed ID: 4203603
    [No Abstract]   [Full Text] [Related]  

  • 7. High-dose intravenous gamma globulin: does it have a role in the treatment of severe erythroblastosis fetalis?
    Chitkara U; Bussel J; Alvarez M; Lynch L; Meisel RL; Berkowitz RL
    Obstet Gynecol; 1990 Oct; 76(4):703-8. PubMed ID: 2120641
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Teeth and Rh incompatibility].
    Kücüküçerler B
    Istanbul Univ Dishekim Fak Derg; 1969 Jun; 3(2):169-73. PubMed ID: 4985168
    [No Abstract]   [Full Text] [Related]  

  • 9. [Perinatal hemolytic disease. Part 1: physiopathology].
    Wirthner D; Hohlfeld P; Tissot JD
    J Gynecol Obstet Biol Reprod (Paris); 1998 Mar; 27(2):135-43. PubMed ID: 9599759
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Current clinical concepts in hemolytic disease and blood group incompatibility.
    Cherry SH
    Prog Clin Biol Res; 1981; 70():205-12. PubMed ID: 6273933
    [No Abstract]   [Full Text] [Related]  

  • 11. [Hemolytic disease of the newborn caused by maternal allo-immunization against erythrocyte antigens other than A, B and rhesus D].
    Monestier M; Rigal D; Juron-Dupraz F; Meyer F
    J Gynecol Obstet Biol Reprod (Paris); 1984; 13(6):671-80. PubMed ID: 6520354
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Rapid and severe development of fetal hemolytic disease due to anti-Kell antibodies].
    Frère MC; Schaaps JP; Thoumsin H; Retz MC; Rif J; Rigo J; De Cortis T; Lambotte R; Senterre J; Sondag-Thull D
    Rev Med Liege; 1995 Feb; 50(2):63-6. PubMed ID: 7899747
    [No Abstract]   [Full Text] [Related]  

  • 13. [Hydrops fetalis caused by isoimmunization against Kell factor (author's transl)].
    Mattern H; Seifert H
    Klin Padiatr; 1980 Sep; 192(5):485-7. PubMed ID: 7192346
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Irregular blood group antibodies during pregnancy: screening is mandatory].
    Semmekrot BA; de Man AJ; Boekkooi PF; van Dijk BA
    Ned Tijdschr Geneeskd; 1999 Jul; 143(28):1449-52. PubMed ID: 10443258
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Erythroblastosis fetalis secondary to Kell immunization.
    Braun RD
    Tex Med; 1972 May; 68(5):104-6. PubMed ID: 5063530
    [No Abstract]   [Full Text] [Related]  

  • 16. Erythroblastosis fetalis with hydrops resulting from anti-Kell isoimmune disease.
    Frigoletto FD; Davies IJ
    Am J Obstet Gynecol; 1977 Apr; 127(8):887. PubMed ID: 851149
    [No Abstract]   [Full Text] [Related]  

  • 17. Kell hemolytic disease of the newborn: A case for expanded prenatal antibody screening.
    Spivey MA; Wilson JT; Taylor HL
    J Ark Med Soc; 1978 Jul; 75(2):73-5. PubMed ID: 149785
    [No Abstract]   [Full Text] [Related]  

  • 18. [Hemolytic disease of the newborn due to Kell sensitization].
    Beller U; Hochner-Celnikier D; Ron M; Palti Z; Beyth Y
    Harefuah; 1981 Jul; 101(1-2):14-5. PubMed ID: 7319365
    [No Abstract]   [Full Text] [Related]  

  • 19. Use of recombinant erythropoietin for the management of severe hemolytic disease of the newborn of a K0 phenotype mother.
    Manoura A; Korakaki E; Hatzidaki E; Saitakis E; Maraka S; Papamastoraki I; Matalliotakis E; Foundouli K; Giannakopoulou C
    Pediatr Hematol Oncol; 2007; 24(1):69-73. PubMed ID: 17130116
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Perinatal research on feto-maternal anti-Kell immunization].
    Gavriil P; Jauniaux E; Lambermont M; Donner C; Avni FE; Rodesch F
    J Gynecol Obstet Biol Reprod (Paris); 1989; 18(6):761-4. PubMed ID: 2689503
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.